Omid Hamic, MD
Authored Items
Best Practices in Immunotherapy – June/July 2017 Vol 8
With single-agent PD-1/PD-L1 therapy, melanoma patients are achieving outcomes once thought impossible for the disease, with some responses lasting more than a decade.
Last modified: June 9, 2018